PRODUCTS

This information is only for healthcare professionals' reference. These products may not be approved and/or licensed in all countries where this website is accessible.

Zejula®

Niraparib

Zejula® (niraparib, ZL-2306) is a highly potent and selective oral, once-daily small molecule poly (ADP-ribose) PARP 1/2inhibitor.


It was approved in March 2017 by the FDA in the United States and in November 2017 by the EMA in the European Union under the trade name Zejula® as a maintenance treatment for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. In April 2020, Zejula® was approved by the US FDA as a monotherapy maintenance treatment for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, regardless of biomarker status. 


Based on the approval status in the United States and European Union by our partner, GSK, Zai Lab obtained the approval for marketing Zejula® in Hong Kong in October 2018 and Macau in June 2019. In December 2019, the China National Medical Products Administration approved the New Drug Application for Zejula® as maintenance therapy for adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy. In September 2020, ZEJULA® was approved by the China NMPA as a maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. 

For inquiries about Zejula®, please email medinfo@zailaboratory.com

Optune®

Tumor Treating Fields

Optune®, a portable device that delivers tumor treating fields(TTFields), is a novel cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division leading to inhibition of tumor growth and death of tumor cells.


Optune® is intended for the treatment of patients with newly diagnosed GBM, after surgery and radiotherapy with adjuvant Temozolomide, concomitant to maintenance Temozolomide, and the treatment of patients with recurrent GBM who have progressed after surgery, radiotherapy and Temozolomide treatment for their primary disease.


Since Dec. 2018, Optune® has been available in Hong Kong (China) for the treatment of glioblastoma multiforme (GBM). Hong Kong is the fourth market after the United States, the European and Japan to have access to this important new medical technology. In May 2020, the China National Medical Products Administration (NMPA) approved the Marketing Authorization Application (MAA) for Optune® in combination with temozolomide for the treatment of patients with newly diagnosed glioblastoma (GBM), and also as a monotherapy for the treatment of patients with recurrent GBM. 


For inquiries about Optune®, please email hkmedinfo@zailaboratory.com